Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.
Adoptive immunotherapy using natural killer (NK) cells is currently under investigation, especially in situations where anti-neoplastic effect is needed but infusion of T cells is considered hazardous, such as in recipients of haematopoietic stem-cell transplantation (HSCT) from haploidentical donors. NK-cell therapy is mainly but not exclusively investigated in the setting of allogeneic stem-cell transplantation. NK cells may induce potent anti-leukaemic and possibly anti-rejection activity, and may even mitigate graft-versus-host disease (GvHD). It remains to be determined whether such effects are clinically important and whether or not they are mediated mainly or exclusively by KIR-HLA class I interactions. Recent advances in graft engineering has provided methods for isolating large numbers of purified NK cells. Several groups have shown that clinical-grade NK cells at doses up to 10(7)/kg may be collected and purified for the purpose of infusion to patients. Early results in a limited number of patients show that these cell doses may be administered without adverse events and possibly without inducing GvHD. Further study is required to determine whether such infusions will be useful in preventing graft rejection, exerting graft-versus-leukaemia effects, and/or hastening immune recovery.
Passweg
Jakob R
JR
Service d'Hématologie, Departement Medecine Interne, Hôpitaux Universitaires de Genève, Genève, Switzerland. jakob.passweg@hcuge.ch
Koehl
Ulrike
U
Uharek
Lutz
L
Meyer-Monard
Sandrine
S
Tichelli
André
A
D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D020544:Graft vs Leukemia Effect; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007694:Killer Cells, Natural / Q000276:immunology* / Q000637:transplantation*; D007938:Leukemia / Q000276:immunology / Q000628:therapy*; D014184:Transplantation, Homologous